J Am Coll Cardiol. 2014 Jan 30;
Authors: Francis GS, Bartos JA, Adatya S
Inotropes have been fundamental to resuscitation of acute cardiogenic shock for decades. Heart failure, and in severe cases, cardiogenic shock are syndromes characterized in many patients by a reduction in myocardial contractile force. While inotropes successfully increase cardiac output, their use has been plagued by excessive mortality due to increased tachycardia and myocardial oxygen consumption leading to arrhythmia and myocardial ischemia. There is a pressing need for new inotropic agents that avoid these harmful effects. This review describes the mechanism of action and the clinical utility of some of the older inotropic agents which are still commonly used, and provides an update for physicians on the development of newer inotropic drugs. The field is rapidly changing and it is likely that new agents will be designed that improve systolic performance without necessarily increasing the myocardial oxygen consumption.
PMID: 24530672 [PubMed - as supplied by publisher]